How to Get Jatenzo in Connecticut

What Jatenzo Is and Why It Differs from Other TRT Formulations

Jatenzo is the only FDA-approved oral testosterone formulation in the United States designed for twice-daily administration with a fat-containing meal. It delivers testosterone undecanoate through intestinal lymphatic absorption, which largely bypasses first-pass hepatic metabolism and avoids the liver-toxicity concerns historically associated with older oral androgens such as methyltestosterone. The FDA approved Jatenzo in March 2019 for adult males with primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired).

The key registration study by Swerdloff et al., published in the Journal of Clinical Endocrinology and Metabolism (2020), enrolled 166 hypogonadal men across a 12-month open-label period. At day 90 to 87% of subjects achieved mean total testosterone concentrations in the normal range (300, 1 to 000 ng/dL). Mean total testosterone at steady state was 504 ng/dL. No serious hepatotoxicity signals emerged over the 12 months of treatment [1].

The capsule comes in three strengths: 158 mg, 198 mg, and 237 mg. Most patients start at 237 mg twice daily. A morning serum testosterone drawn 6 hours post-dose at week 4 guides titration: if the average of two C-avg values exceeds 1 to 050 ng/dL, the prescriber steps down; values below 400 ng/dL prompt a step up. This titration algorithm is described in the Jatenzo prescribing information maintained by the FDA [2].

One clinically meaningful difference from topical gels or injections: Jatenzo does not carry the same risk of skin-to-skin testosterone transfer to partners or children, a concern flagged in the FDA's 2009 black-box warning update for topical testosterone products [3]. Patients who have had compliance problems with daily gels or who cannot tolerate injections often find the oral route preferable.

Blood pressure elevation is a documented adverse effect. The FDA label carries a warning that Jatenzo can raise systolic blood pressure by a mean of approximately 3 to 5 mmHg; baseline and follow-up blood pressure measurement is mandatory. Patients with uncontrolled hypertension should not start Jatenzo until blood pressure is controlled [2].

Connecticut-Specific Prescribing Rules

Connecticut permits telehealth prescribing of controlled substances under conditions that align with the federal Ryan Haight Act and the DEA's 2023 telemedicine special registration proposals. A prescriber licensed in Connecticut may issue a Schedule III controlled substance prescription via synchronous audio-video telehealth without a prior in-person visit, provided the prescriber conducts a thorough evaluation and the encounter meets documentation standards outlined by the Connecticut Department of Public Health telehealth guidance and the DEA's interim final rule on telemedicine prescribing.

Testosterone is classified as a Schedule III controlled substance under 21 USC 812 [4]. This means the prescriber must hold an active DEA registration, the prescription cannot be phoned in (electronic or written Rx only), and refills are limited to five within six months of the original date. Telehealth platforms operating in Connecticut must verify prescriber DEA and state licensure before routing the order to a pharmacy.

Prescriber scope in Connecticut breaks down as follows. Physicians (MD/DO) may prescribe independently. Advanced practice registered nurses (APRNs) in Connecticut hold independent prescriptive authority under Connecticut General Statutes §20-94a and may prescribe Jatenzo without a collaborating physician agreement after completing the required 3-year collaborative period. Physician assistants (PAs) prescribe under a supervision agreement and must have testosterone specifically listed or covered under their scope agreement. Any patient receiving a telehealth Jatenzo prescription should confirm that the platform's prescriber holds a current Connecticut license and DEA number before the encounter.

Required Lab Work Before Starting Jatenzo

No reputable prescriber will initiate testosterone therapy without objective laboratory confirmation of hypogonadism. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends measuring total testosterone on at least two separate morning occasions (8, 10 AM) before diagnosis, because testosterone peaks in the early morning and single measurements can be misleading [5].

The minimum pre-treatment panel in Connecticut, consistent with Endocrine Society guidance and standard HealthRX clinical protocols, includes:

• Total testosterone (two morning draws, at least one week apart)
• Free testosterone or bioavailable testosterone if total is borderline (200 to 400 ng/dL) or if SHBG abnormality is suspected
• LH and FSH (to differentiate primary from secondary hypogonadism)
• Complete blood count with hematocrit
• Comprehensive metabolic panel (liver function baseline)
• PSA for men age 40 and older, or any age with risk factors for prostate cancer
• Blood pressure measurement (mandatory per FDA label)

Hematocrit is especially important because testosterone therapy can stimulate erythropoiesis, raising hematocrit and increasing thrombosis risk if it exceeds approximately 54% [6]. The American Urological Association's 2022 guidelines on testosterone deficiency suggest withholding therapy if hematocrit exceeds 54% at baseline [6].

Most commercial labs in Connecticut (Quest Diagnostics, LabCorp) can process these panels with a physician order. Many telehealth platforms generate a lab requisition electronically; the patient completes the draw at a local patient service center and results are reviewed at the telehealth visit. Turnaround for standard testosterone panels is typically 24 to 48 hours.

How the Telehealth Prescribing Process Works in Connecticut

Telehealth has made access to hypogonadism evaluation substantially faster for Connecticut patients who live outside major metropolitan areas or who cannot take time off work for in-person specialist appointments. The general workflow follows five steps.

Step 1: Select a platform licensed in Connecticut. Confirm the prescriber holds a Connecticut state medical or APRN license and a valid DEA registration. Platforms operating nationally sometimes restrict Schedule III prescribing in certain states; verify before paying any fees.

Step 2: Complete intake forms and upload labs. Most platforms require prior lab results or order labs through an affiliated draw site. If you have existing testosterone results from a primary care visit, upload them. If not, the platform issues a lab order and you complete the draw before the video visit.

Step 3: Attend the synchronous video visit. The prescriber will review your symptoms (fatigue, low libido, erectile dysfunction, loss of muscle mass, mood changes), examine your lab values, take a medication and medical history, measure or confirm blood pressure, and discuss treatment options. A typical initial visit runs 20 to 40 minutes.

Step 4: Receive the electronic prescription. If Jatenzo is appropriate, the prescriber sends an electronic controlled-substance prescription (EPCS) to your chosen Connecticut-licensed pharmacy or a mail-order pharmacy licensed to ship into Connecticut. The DEA's EPCS regulations require two-factor authentication at the prescriber level [7].

Step 5: Pharmacy dispenses and ships. Retail pharmacies (CVS, Walgreens, Stop and Shop) in Connecticut stock or can order Jatenzo. Specialty and mail-order pharmacies can ship to Connecticut addresses. Estimated delivery after prescription verification is 2 to 5 business days for retail pickup and 5 to 10 business days for mail order.

Insurance Coverage and Prior Authorization in Connecticut

Coverage for Jatenzo varies significantly by payer. Connecticut Medicaid (HUSKY Health) covers Jatenzo for male hypogonadism with prior authorization. Commercial plans in Connecticut follow their own formulary tiers; Jatenzo is frequently placed on Tier 3 or non-preferred specialty, making prior authorization common across most major commercial payers including Anthem BCBS CT, Cigna, Aetna, and UnitedHealthcare.

A prior authorization for Jatenzo in Connecticut typically requires:

• Two documented morning total testosterone values below 300 ng/dL (some payers use 350 ng/dL as a cutoff)
• Documented clinical symptoms consistent with hypogonadism
• Documentation of the cause of hypogonadism (primary vs. secondary) where available
• Prescriber attestation that the patient has a confirmed diagnosis per established criteria
• In some cases, evidence that at least one other testosterone formulation was tried and failed or is contraindicated

The Endocrine Society's position statement on testosterone therapy states: "We recommend making the diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone levels." Payers use language nearly identical to this guideline as their coverage criterion [5].

If prior authorization is denied, you have the right to appeal under Connecticut insurance law. Many telehealth platforms have in-house PA teams who handle the appeal process, including peer-to-peer review calls between the payer's medical director and the treating prescriber. Approval rates on first appeal are meaningful when clinical documentation is thorough; having two low testosterone values and documented symptom burden strengthens any appeal significantly.

Cash-pay patients and those whose insurance does not cover Jatenzo should check the Tolmar patient assistance program and GoodRx or manufacturer copay cards, which can reduce out-of-pocket cost for commercially insured patients who do not use government insurance. Jatenzo's retail cash price at Connecticut pharmacies runs approximately $500 to $600 per month without assistance; manufacturer savings cards may reduce that to under $100 for eligible patients.

503A Compounding of Oral Testosterone Undecanoate in Connecticut

Licensed 503A compounding pharmacies in Connecticut may prepare oral testosterone undecanoate capsules for patients who have a valid prescription from a licensed prescriber. Section 503A of the Federal Food, Drug, and Cosmetic Act permits compounding pharmacies to prepare individualized preparations based on a patient-specific prescription, provided the drug is not on the FDA's withdrawn or removed list and certain other conditions are met [8].

Oral testosterone undecanoate is not on the FDA's list of drugs withdrawn for safety reasons, and compounded versions may be prepared by a 503A pharmacy for a specific patient. However, there are meaningful clinical distinctions between FDA-approved Jatenzo and a compounded oral testosterone undecanoate product. Jatenzo uses a proprietary lipid self-emulsifying drug delivery system (SEDDS) formulation that is integral to its predictable lymphatic absorption and bioavailability profile. A compounded capsule using a different excipient base may not replicate the pharmacokinetics demonstrated in the Swerdloff et al. registration trial [1].

The FDA's guidance on compounding of human drug products advises clinicians and patients that compounded products lack the safety and efficacy review of FDA-approved drugs [8]. This does not mean compounded testosterone undecanoate is unsafe, but it means the specific absorption and titration data from the Jatenzo trials do not directly apply to a compounded version. Prescribers should document the clinical rationale if choosing a compounded product over brand Jatenzo.

Connecticut 503A pharmacies must hold a Connecticut Pharmacy License from the Connecticut Department of Consumer Protection and comply with USP Chapter 795 standards for non-sterile compounding. Patients should verify their compounding pharmacy's licensure before filling.

Monitoring After Starting Jatenzo

The FDA-approved prescribing information specifies a monitoring testosterone draw at week 4, performed as a morning sample collected 6 hours after the morning dose. This C-avg estimation guides the three-way titration decision: maintain, step down, or step up [2]. Follow-up monitoring per standard endocrine practice then continues at 3 months, 6 months, and annually thereafter.

At each follow-up visit, the clinician should assess:

• Total testosterone (C-avg estimation at week 4; trough or mid-interval at subsequent visits)
• Hematocrit and hemoglobin (testosterone-induced erythrocytosis can develop gradually over 3 to 6 months)
• Blood pressure (Jatenzo's label warning requires ongoing monitoring throughout treatment)
• PSA in men age 40 or older (annually, or sooner if symptoms suggest prostate pathology)
• Symptom reassessment using a validated tool such as the AMS (Aging Males' Symptoms) scale

A 2020 meta-analysis published in the Journal of Clinical Endocrinology and Metabolism (N=3,236 across 35 randomized trials) found that testosterone therapy produced statistically significant improvements in sexual function, energy, and mood scores versus placebo across hypogonadal men, with a standardized mean difference of 0.42 (95% CI 0.30, 0.54) for sexual function outcomes [9]. These effect sizes justify the monitoring investment.

If hematocrit exceeds 54% at any monitoring visit, the Endocrine Society guidelines recommend dose reduction or temporary discontinuation until hematocrit normalizes. Therapeutic phlebotomy is sometimes used in refractory cases [5].

Transferring an Existing Jatenzo Prescription to Connecticut

Patients relocating to Connecticut with an existing Jatenzo prescription from another state face a Schedule III controlled-substance transfer question. Retail pharmacies (CVS, Walgreens) within the same chain can transfer a Schedule III prescription once under federal DEA rules, provided the original prescription still has authorized refills remaining. A Schedule III prescription allows up to five refills within six months of issue. After the original prescription expires, a new prescription from a Connecticut-licensed prescriber is required.

If you are mid-course in a telehealth program with an out-of-state platform, check whether the prescriber holds a Connecticut license. Many national telehealth providers maintain prescriber licensure in all 50 states. If they do not, the platform should transfer your care to a Connecticut-credentialed clinician within the same network, or you will need to initiate a new evaluation with a Connecticut-licensed provider. Bring your prior lab results and prescription history to minimize repeat testing.

The DEA's rules on Schedule III prescription transfers specify that a pharmacist may transfer a Schedule III prescription to another pharmacy once, provided the original prescription has not yet been dispensed in full and refills remain [7]. A transferred prescription must be voided at the originating pharmacy and annotated with the receiving pharmacy's DEA number and pharmacist name.

Dosing and Administration Practical Points

Jatenzo must be taken with food containing fat. The prescribing information specifies that the meal should ideally contain at least 10 to 20 grams of fat to support lymphatic absorption. Taking Jatenzo with a fat-free meal or on an empty stomach reduces absorption substantially and produces subtherapeutic testosterone levels. Patients who are intermittent fasting or following very low-fat diets need to plan their dosing schedule around meals [2].

The twice-daily schedule means doses are typically taken with breakfast and dinner. Spacing of approximately 10 to 12 hours between doses is preferred. If a dose is missed, the patient should take it as soon as remembered with food, then resume the normal schedule; doubling up on doses is not recommended per the label [2].

Capsules should be swallowed whole and not crushed or chewed, because the lipid formulation encapsulation is part of the drug delivery system. Storage is at room temperature (68°F to 77°F / 20°C to 25°C), away from moisture and heat.

Finding a Connecticut Provider or Telehealth Platform

Several pathways exist for Connecticut residents. Academic medical centers with endocrinology or urology departments, including Yale Medicine in New Haven and UConn Health in Farmington, maintain hypogonadism clinics staffed by endocrinologists and urologists familiar with the full range of testosterone formulations including Jatenzo. Wait times for specialist appointments may run 4 to 12 weeks depending on referral demand.

Primary care physicians in Connecticut with an interest in men's health may also prescribe Jatenzo; the drug does not require specialist training, though providers should be familiar with the FDA label's titration algorithm and blood pressure monitoring requirements.

Telehealth platforms licensed in Connecticut offer the fastest access pathway, often scheduling an initial evaluation within 48 to 72 hours of sign-up. When evaluating a telehealth provider for Jatenzo specifically, ask:

• Does the prescriber hold a current Connecticut license and active DEA registration?
• Does the platform use EPCS-compliant software for Schedule III prescriptions?
• Does the platform have a prior authorization support team?
• Which Connecticut-licensed pharmacies does the platform route prescriptions to?
• What is the follow-up monitoring protocol, and who reviews titration labs?

A telehealth provider unable to answer these questions clearly may lack the infrastructure to safely manage Schedule III testosterone prescribing in Connecticut.

The American Urological Association's 2022 testosterone deficiency clinical guideline classifies oral testosterone undecanoate as a guideline-supported treatment option alongside injections, gels, patches, and pellets, noting that the oral route offers a meaningful alternative for men who prefer to avoid injections or topical products [6].